TABLE 2.
Parameter estimates assessing the influence of exposure on LVEF events.
| Exposure | Model | Parameter | Estimate (95% CI) | P‐value |
|---|---|---|---|---|
| Osimertinib | Base model | Intercept | −12.8 (−19.3, −6.02) | <.001 |
| Slope | 1.02 (0.304, 1.7) | .006 | ||
| Final model | Intercept | −6.36 (−13.6, 1.01) | .090 | |
| Slope | 0.921 (0.209, 1.61) | .012 | ||
| Baseline LVEF | −0.087 (−0.134, −0.042) | <.001 | ||
| AZ5104 | Base model | Intercept | −10.5 (−15.1, −5.9) | <.001 |
| Slope | 1.02 (0.382, 1.64) | .002 | ||
| Final model | Intercept | −4.38 (−9.88, 1.07) | .115 | |
| Slope | 0.927 (0.292, 1.56) | .004 | ||
| Baseline LVEF | −0.087 (−0.134, −0.041) | <.001 |
Note: The base models used AUCss of osimertinib/AZ5104 as the predictor variable and the final models used AUCss of osimertinib/AZ5104 with baseline LVEF as a covariate.
Abbreviations: CI, confidence interval; LVEF, left ventricular ejection fraction.